These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 22726547)
21. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637 [TBL] [Abstract][Full Text] [Related]
22. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis. Polzer K; Neubert K; Meister S; Frey B; Baum W; Distler JH; Gückel E; Schett G; Voll RE; Zwerina J Arthritis Rheum; 2011 Mar; 63(3):670-80. PubMed ID: 21360496 [TBL] [Abstract][Full Text] [Related]
23. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma. Bai Y; Su X Asia Pac J Clin Oncol; 2021 Feb; 17(1):29-35. PubMed ID: 32920949 [TBL] [Abstract][Full Text] [Related]
24. The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma. Liu Y; Li B; Chen X; Xiong H; Huang C Expert Rev Hematol; 2024; 17(1-3):47-54. PubMed ID: 38319240 [TBL] [Abstract][Full Text] [Related]
25. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Colucci S; Brunetti G; Rizzi R; Zonno A; Mori G; Colaianni G; Del Prete D; Faccio R; Liso A; Capalbo S; Liso V; Zallone A; Grano M Blood; 2004 Dec; 104(12):3722-30. PubMed ID: 15308561 [TBL] [Abstract][Full Text] [Related]
26. Role of the bone marrow microenvironment in multiple myeloma. Roodman GD J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796 [TBL] [Abstract][Full Text] [Related]
27. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation. Ichikawa H; Aggarwal BB Clin Cancer Res; 2006 Jan; 12(2):662-8. PubMed ID: 16428513 [TBL] [Abstract][Full Text] [Related]
28. Dickkopf-1: a suitable target for the management of myeloma bone disease. Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987 [TBL] [Abstract][Full Text] [Related]
29. Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2. Yen CH; Hsu CM; Hsiao SY; Hsiao HH Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937821 [TBL] [Abstract][Full Text] [Related]
30. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218 [TBL] [Abstract][Full Text] [Related]
31. Gene silencing of the BDNF/TrkB axis in multiple myeloma blocks bone destruction and tumor burden in vitro and in vivo. Ai LS; Sun CY; Wang YD; Zhang L; Chu ZB; Qin Y; Gao F; Yan H; Guo T; Chen L; Yang D; Hu Y Int J Cancer; 2013 Sep; 133(5):1074-84. PubMed ID: 23420490 [TBL] [Abstract][Full Text] [Related]
32. Tumor-host cell interactions in the bone disease of myeloma. Fowler JA; Edwards CM; Croucher PI Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487 [TBL] [Abstract][Full Text] [Related]
33. Myeloma bone disease and proteasome inhibition therapies. Terpos E; Sezer O; Croucher P; Dimopoulos MA Blood; 2007 Aug; 110(4):1098-104. PubMed ID: 17494860 [TBL] [Abstract][Full Text] [Related]
34. Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades. Ang E; Pavlos NJ; Rea SL; Qi M; Chai T; Walsh JP; Ratajczak T; Zheng MH; Xu J J Cell Physiol; 2009 Aug; 220(2):450-9. PubMed ID: 19365810 [TBL] [Abstract][Full Text] [Related]
35. The effects of proteasome inhibitors on bone remodeling in multiple myeloma. Zangari M; Suva LJ Bone; 2016 May; 86():131-8. PubMed ID: 26947893 [TBL] [Abstract][Full Text] [Related]
37. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Giuliani N; Colla S; Rizzoli V Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315 [TBL] [Abstract][Full Text] [Related]
38. Bortezomib inhibits human osteoclastogenesis. von Metzler I; Krebbel H; Hecht M; Manz RA; Fleissner C; Mieth M; Kaiser M; Jakob C; Sterz J; Kleeberg L; Heider U; Sezer O Leukemia; 2007 Sep; 21(9):2025-34. PubMed ID: 17581612 [TBL] [Abstract][Full Text] [Related]
40. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling. Kaiser MF; Heider U; Mieth M; Zang C; von Metzler I; Sezer O Eur J Haematol; 2013 Apr; 90(4):263-72. PubMed ID: 23311753 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]